Mindset Pharma (MSET.C) announced they have filed a new patent with the US Patent and Trade Office (USPTO), extending its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs….
August 24, 2021
PolarityTE (PTE.Q) has provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to the Company’s Investigational New Drug Application (IND) for SkinTE®, which was…
It seems the apes are back at it. Loading up on AMC Entertainment. And for good reason. AMC has one of the best looking technical set ups right now….
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
Tonix Pharmaceuticals (TNXP.Q) announced today that it has received the official minutes from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA)…
Bioasis (BTI.V) is a company that is delivering hope to patients suffering with neurological diseases and disorders. It is the Blood-Brain Barrier delivery company. The Blood-Brain Barrier…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain….
Bioasis is a preclinical biopharmaceutical company focused on research and early-stage development of technologies and products for the treatment of patients with the central nervous system, or CNS, diseases,…
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an…